Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephanie Cox

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
The Lancet. HIV|February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trialAlan Winston, Frank A Post, Edwin DeJesus, et al.
The Lancet. HIV|December 18, 2018
Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trialJoseph J Eron, Jean-Daniel Lelievre, Robert Kalayjian, et al.
Plos One|January 30, 2020
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimensGregory D Huhn, Moti Ramgopal, Mamta K Jain, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 18, 2010
A novel custom resequencing array for dilated cardiomyopathyRebekah S Zimmerman, Stephanie Cox, Neal K Lakdawala, et al.
Antimicrobial Agents and Chemotherapy|July 25, 2018
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B InfectionAndrea L Cathcart, Henry Lik-Yuen Chan, Neeru Bhardwaj, et al.
The Lancet. HIV|July 1, 2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOnyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, et al.
AIDS (London, England)|September 29, 2021
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individualsBrian Moldt, Huldrych F Günthard, Kimberly A Workowski, et al.
The Lancet. HIV|July 15, 2024
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trialDavid A Wohl, Christoph D Spinner, Jason Flamm, et al.
JAMA Network Open|June 1, 2026
Early Neurodevelopmental Outcomes in Children With Congenital Heart DiseaseMike Seed, Dawn Ilardi, Valerie Rofeberg, et al.
The New England Journal of Medicine|November 27, 2024
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse PersonsColleen F Kelley, Maribel Acevedo-Quiñones, Allison L Agwu, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
The Lancet. HIV|February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trialAlan Winston, Frank A Post, Edwin DeJesus, et al.
The Lancet. HIV|December 18, 2018
Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trialJoseph J Eron, Jean-Daniel Lelievre, Robert Kalayjian, et al.
Plos One|January 30, 2020
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimensGregory D Huhn, Moti Ramgopal, Mamta K Jain, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 18, 2010
A novel custom resequencing array for dilated cardiomyopathyRebekah S Zimmerman, Stephanie Cox, Neal K Lakdawala, et al.
Antimicrobial Agents and Chemotherapy|July 25, 2018
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B InfectionAndrea L Cathcart, Henry Lik-Yuen Chan, Neeru Bhardwaj, et al.
The Lancet. HIV|July 1, 2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOnyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, et al.
AIDS (London, England)|September 29, 2021
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individualsBrian Moldt, Huldrych F Günthard, Kimberly A Workowski, et al.
The Lancet. HIV|July 15, 2024
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trialDavid A Wohl, Christoph D Spinner, Jason Flamm, et al.
JAMA Network Open|June 1, 2026
Early Neurodevelopmental Outcomes in Children With Congenital Heart DiseaseMike Seed, Dawn Ilardi, Valerie Rofeberg, et al.
The New England Journal of Medicine|November 27, 2024
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse PersonsColleen F Kelley, Maribel Acevedo-Quiñones, Allison L Agwu, et al.
Pageof 7